Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
<sup>18</sup>F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response
339
Zitationen
2
Autoren
2009
Jahr
Abstract
Multimodality imaging, as represented by its greatest exponent, PET/CT, has a firm place in the evaluation of a patient presenting with cancer. With 18F-FDG, PET/CT is rapidly becoming the key investigative tool for the staging and assessment of cancer recurrence. In the last 5 y, PET/CT has also gained widespread acceptance as a key tool used to demonstrate early response to intervention and therapy. In this setting, a major clinical need is being addressed with 18F-FDG PET/CT, because of its inherent ability to demonstrate (before other markers of response) if disease modification has occurred. This review presents available evidence to this effect.
Ähnliche Arbeiten
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 · 29.117 Zit.
fastp: an ultra-fast all-in-one FASTQ preprocessor
2018 · 28.449 Zit.
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 · 21.367 Zit.
Robust uncertainty principles: exact signal reconstruction from highly incomplete frequency information
2006 · 15.721 Zit.
Image processing with ImageJ
2004 · 11.903 Zit.